ReviewJournal of the Pediatric Infectious Diseases Society2022
Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.
Review in Journal of the Pediatric Infectious Diseases Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation.Clinical microbiology reviews · 2026Review
- The respiratory microbiome: dynamics from health to disease.FEMS microbiology ecology · 2026Review
- Review
- Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.The European respiratory journal · 2025Observational
- Cystic fibrosis airway epithelial cells have an exaggerated response to hypoxia that is partially reversible through transmembrane receptor modulation.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- Exploring the role of microbiome in cystic fibrosis clinical outcomes through a mediation analysis.mSystems · 2025Article
- Article
- Review
- Early nasal microbiota and subsequent respiratory tract infections in infants with cystic fibrosis.Communications medicine · 2024Article
- Highly Effective Modulator Therapy: Implications for the Microbial Landscape in Cystic Fibrosis.International journal of molecular sciences · 2024Review
- Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis.Mycopathologia · 2024Review
- Facemask acne attenuation through modulation of indirect microbiome interactions.NPJ biofilms and microbiomes · 2024Article
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.Nature communications · 2024Observational
- Antibiofilm activity ofBiofilm · 2024Article
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.Research square · 2024Article
- The Impact of Antimicrobial Resistance in Cystic Fibrosis.Journal of clinical medicine · 2024Review
- Insights into the role of the respiratory tract microbiome in defense against bacterial pneumonia.Current opinion in microbiology · 2024Review
- Review
- The airway microbiome of persons with cystic fibrosis correlates with acquisition and microbiological outcomes of incidentFrontiers in microbiology · 2024Article
- Comparative genomics of clinicalMicrobiology (Reading, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lower respiratory tract infections are a leading contributor to morbidity and mortality in persons with cystic fibrosis (pwCF). Traditional respiratory tract surveillance culturing has focused on a limited range of classic pathogens; however, comprehensive culture and culture-independent molecular approaches have demonstrated complex communities highly unique to each individual. Microbial community structure evolves through the lifetime of pwCF and is associated with baseline disease state and rates of disease progression including occurrence of pulmonary exacerbations. While molecular analysis of the airway microbiome has provided insight into these dynamics, challenges remain including discerning not only "who is there" but "what they are doing" in relation to disease progression. Moreover, the microbiome can be leveraged as a multi-modal biomarker for both disease activity and prognostication. In this article, we review our evolving understanding of the role these communities play in pwCF and identify challenges in translating microbiome data to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.